Is the price fair?
What RARE's price assumes
Ultragenyx Pharmaceutical Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 3.15× revenue.
3.15
Price / sales · no P/E: the last twelve months did not end in a profit
Details›
- EV / EBIToperating margin −74%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $2.70B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.